Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
By C. Ruff, R. P. Giugliano, E. Braunwald, Elaine B. Hoffman, Naveen Deenadayalu, M. Ezekowitz, A. Camm, J. Weitz, Basil S Lewis, A. Parkhomenko and 2 more. The Lancet, 2014
4,384 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Neurology
View Paper: https://www.semanticscholar.org/paper/0f0ca1c018590d242c76e260b759e845db66d75f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Epidemiology
Citations in the corpus
- Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. (2014, result): “In contrast, DOACs were associated with a significant 25% relative increase in major gastrointestinal bleeding in the AF trials, whereas in the treatment of VTE, no difference in major gastrointestinal bleeding rates was seen.(10) The reasons for this discrepancy are at present unclear but may inclu”
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or nonVKA oral anticoagulants (NOACs) markedly reduces stroke and mortality in AF patients.(38,39) Other interventions such as rhythm control and rate control improve AF-related symptoms and may preserve cardiac function, but have not demo”
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, background): “Furthermore, the prolongation of the PT/INR by NOACs can be misleading during the transition of a NOAC to a VKA.”